Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q1FY25 results:
Financial Highlights:
- GlaxoSmithKline Pharmaceuticals Limited (GSK) today announced its financial results for quarter ended June 30, 2024. Revenue from operations for the quarter grew by 10% at Rs 811 crore. Profit After Tax (PAT) for the quarter at Rs 182 crore.
- The company continued to deliver a strong growth of 10% with key brands such as Calpol, Augmentin, T-Bact and gaining market share. In addition, the Respiratory portfolio comprising Nucala and Trelegy delivered a growth of 57% by further improving access to more patients.
Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said “We continue our growth momentum across General Medicines and Vaccines portfolios while maintaining profitability. As we celebrate hundred years of our operations in India, we remain committed to pursuing new growth opportunities, enhancing our leadership in key therapeutic areas and advancing our innovative omnichannel strategies to further enhance customer experience.”